In light of these findings, we assessed the potential of ASM inhibition as a treatment for FD—as a proof-of-concept study, we cross-bred Ac-deficient mice to Asm-deficient mice and monitored ceramide accumulation, survival, and disease manifestations in FD mice upon co-ablation of Asm. The gene discussed is ASAH1; the disease is Fabry disease.